SEP 9, 2026 · PHASE 1/2 TRIAL
A Study of PRMT5 Inhibitor BAY 3713372 in Participants With MTAP-deleted Solid Tumors
ClinicalTrials.gov
This is a first-in-human Phase 1/2 trial registration with no results posted; it describes planned enrollment and primary endpoints focused on safety, tolerability, and pharmacokinetics in an early-stage investigation of a novel PRMT5 inhibitor.
Reported
Estimated enrollment450
Study phasePhase 1/Phase 2
Primary outcome measure (dose esc…Number of participants with TEAEs, TESAEs,…